Abstract 307P
Background
Uterine leiomyosarcoma (uLMS) is a rare, aggressive subtype of uterine cancer. Metastatic uLMS is known for its poor prognosis. uLMS have recurrence rates of 50-70%, with an overall 5-year survival less than 15% in advanced stages. The main treatment for localized uLMS is surgery. For unresectable or advanced uLMS, other options such as chemotherapy and hormonal therapy can be offered.
Methods
We conducted a search across 5 databases, Google Scholar, Science Direct, PubMed, EMBASE & Scopus for studies within the last 15 years. We included studies that recorded combination chemotherapy/hormonal therapy as the treatment regime for histologically confirmed metastatic/unresectable uLMS. We excluded studies with <5 samples, those that included other uterine cancers & non-English articles. Quality of the studies were assessed by the Newcastle-Ottawa Scale (NOS).
Results
We found 10 studies, with a total of 427 metastatic uLMS patients. Combination chemotherapy had much higher rates of response & progression-free survival compared to hormonal therapy. Gemcitabin-docetaxel was the most common regime, with high effectivity. Addition of targeted therapy did not improve outcomes significantly. However, combination chemotherapy had a much higher proportion of grade 3-4 toxicity. Most common side effects were myelosuppression, fatigue & liver toxicity, resulting in much higher rates of therapy discontinuation due to the side effects. Hormonal therapy was much more tolerable, with common side effects including hot flashes, weight gain, muscle pain & joint pain. Unfortunately, hormonal therapy had higher proportions of therapy discontinuation due to disease progression, and had lower response rates, shorter overall survival & progression-free survival. Overall, patient-specific factors play a crucial role in treatment decisions. Hormonal therapy has a more attractive side effect profile, while combination chemotherapy though more aggressive may be favorable in cases requiring rapid tumor control.
Conclusions
uLMS is an aggressive cancer with hormonal therapy & combination chemotherapy as treatment options. Hormonal therapy has a better side effect profile, with chemotherapy having better effectivity and survival rates.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
P. Angel.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
551P - Real-world incidence and outcomes of immune-related adverse events in NSCLC patients
Presenter: Andrea Knox
Session: Poster Display
Resources:
Abstract
552P - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
Presenter: Yasushi Goto
Session: Poster Display
Resources:
Abstract
553P - Preceding plasma EGFR vs upfront tissue NGS for advanced NSCLC in the Chinese population: A single centre experience in Hong Kong
Presenter: Janet Du
Session: Poster Display
Resources:
Abstract
554P - Comparison of the analytical performance of endobronchial ultrasound-guided transbronchial needle aspiration and other sampling methods for the Oncomine Dx target test: An observational study
Presenter: Kazuhito Miyazaki
Session: Poster Display
Resources:
Abstract
555P - Quality of life in patients with stage IV non-small cell lung cancer and the influence of druggable mutations over time: A prospective, territory-wide study in Hong Kong
Presenter: Jason C S Ho
Session: Poster Display
Resources:
Abstract
556P - Results from the phase I study on efficacy and safety of iruplinalkib (WX-0593) for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who received prior second-generation ALK tyrosine kinase inhibitors (TKIs)
Presenter: xuezhi Hao
Session: Poster Display
Resources:
Abstract
557P - Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy
Presenter: Shasha Wang
Session: Poster Display
Resources:
Abstract
558P - Treatment duration and adherence of brigatinib as second-line treatment after crizotinib for ALK+ NSCLC in South Korea
Presenter: Jeong Eun Lee
Session: Poster Display
Resources:
Abstract
559P - Comprehensive survey of AACR GENIE database revealed a wide range of TMB distribution among all three classes (I, II, III) of BRAF mutated NSCLC
Presenter: Zhaohui Arter
Session: Poster Display
Resources:
Abstract
560P - Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC
Presenter: Chengdi Weng
Session: Poster Display
Resources:
Abstract